Farlow M - Search Results

1

Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.

Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D. Voss T, et al. Among authors: farlow m. Alzheimers Dement (N Y). 2018 Apr 26;4:173-181. doi: 10.1016/j.trci.2018.03.004. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 29955661 Free PMC article.

2

Effective pharmacologic management of Alzheimer's disease.

Farlow MR, Cummings JL. Farlow MR, et al. Am J Med. 2007 May;120(5):388-97. doi: 10.1016/j.amjmed.2006.08.036. Am J Med. 2007. PMID: 17466645 Review.

3

A modern hypothesis: The distinct pathologies of dementia associated with Parkinson's disease versus Alzheimer's disease.

Farlow MR, Cummings J. Farlow MR, et al. Dement Geriatr Cogn Disord. 2008;25(4):301-8. doi: 10.1159/000119104. Epub 2008 Mar 3. Dement Geriatr Cogn Disord. 2008. PMID: 18311077 Review.

4

Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.

Cummings JL, Farlow MR, Meng X, Tekin S, Olin JT. Cummings JL, et al. Clin Drug Investig. 2010;30(1):41-9. doi: 10.2165/11531270-000000000-00000. Clin Drug Investig. 2010. PMID: 19995097 Clinical Trial.

5

Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.

Farlow MR, Cummings JL, Olin JT, Meng X. Farlow MR, et al. Am J Alzheimers Dis Other Demen. 2010 Jun;25(4):347-52. doi: 10.1177/1533317510365344. Epub 2010 Apr 14. Am J Alzheimers Dis Other Demen. 2010. PMID: 20392862 Free PMC article.

6

Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.

Cummings JL, Ferris SH, Farlow MR, Olin JT, Meng X. Cummings JL, et al. Dement Geriatr Cogn Disord. 2010;29(5):406-12. doi: 10.1159/000296073. Epub 2010 May 21. Dement Geriatr Cogn Disord. 2010. PMID: 20502014 Clinical Trial.

7

Reviewing the role of donepezil in the treatment of Alzheimer's disease.

Doody RS, Cummings JL, Farlow MR. Doody RS, et al. Curr Alzheimer Res. 2012 Sep;9(7):773-81. doi: 10.2174/156720512802455412. Curr Alzheimer Res. 2012. PMID: 22175653 Review.

8

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Farlow M, et al. Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5. Alzheimers Dement. 2012. PMID: 22672770 Clinical Trial.

9

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity.

Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, Liu L, Mackell J, Fain R. Ferris S, et al. Among authors: farlow m. Alzheimers Res Ther. 2013 Feb 21;5(1):12. doi: 10.1186/alzrt166. eCollection 2013. Alzheimers Res Ther. 2013. PMID: 23433097 Free PMC article.

10

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P. Cummings JL, et al. Among authors: farlow m. CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6. CNS Neurosci Ther. 2013. PMID: 23462265 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

698 results

Search Page

Filters